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Dear Editor, 
Acinetobacter baumannii is an opportunistic 
pathogen responsible for severe infections and is 
associated with nosocomial outbreaks worldwide [1,2]. 
Carbapenems are the agents of choice to treat these 
infections, but multidrug-resistant isolates are being 
reported in hospitals worldwide [1]. One of the most 
important mechanisms of resistance to carbapenems is 
the production of carbapenem-hydrolyzing class D β-
lactamases encoded by blaOXA-23-like, blaOXA-40-like, 
blaOXA-51-like, blaOXA-58-like, and blaOXA-143-like genes 
[1]. The increase of the resistance in Acinetobacter 
baumannii makes the treatment due to these last-resort 
drugs challenging, as life-threatening infections due to 
carbapenem-resistant isolates are on the rise in 
developing countries such as Bolivia. 
The aim of this work was to analyze an especially 
virulent strain of Acinetobacter baumannii, named 
Bo995, obtained from a 51-year-old woman who was 
admitted to Viedma Hospital, a tertiary care university 
hospital in Cochabamba, Bolivia, with a diagnosis of 
odontogenic abscess; this process rapidly evolved to a 
severe sepsis and mediastinitis, which required surgery, 
exploratory thoracotomy, and drainage. One day after 
the procedure, the patient was admitted to the intensive 
care unit (ICU), where Acinetobacter baumannii with 
resistance to different antibiotics, including imipenem, 
was isolated from a tracheal aspirate. She died 10 days 
later due to general sepsis. In this work, we present the 
characterization of this virulent strain with regard to its 
antibiotic resistance and the identification of 
carbapenemases as a mechanism of carbapenem 
resistance. 
 
The study 
In order to analyze the antibiotic resistance profile, 
minimum inhibitory concentrations (MICs) were 
determined by broth microdilution method following 
the recommendations of the Clinical and Laboratory 
Standards Institute (CLSI) of the most common 
antibiotics used in treatment. The results revealed that 
this isolate was resistant to all the antibiotics tested, 
showing the following MIC values: imipenem (MSD, 
Madrid, Spain), 64 g/mL; meropenem (AstraZeneca, 
Wilmington, USA), 64 g/mL; ceftazidime 
(GlaxoWellcome, Madrid, Spain), > 128 g/mL; 
cefotaxime (Aventis, Madrid, Spain), > 128 g/mL; 
cefepime (BMS, Sermoneta, Italy), 64 g/mL; 
gentamicin (MSD, Madrid, Spain), >128 g/mL; 
amikacin (BMS, Sermoneta, Italy), 32 g/mL; and 
norfloxacin, (MSD, Madrid, Spain), > 128 g/mL. 
This isolate, resistant to all antibiotics tested except 
colistin, could represent the “tip of the iceberg” of the 
population of A. baumannii isolates obtained from the 
Viedma Hospital, where the rates among the total 
population during 2014 were reported to be very high 
and the antibiogram data showed that 72.9% of the 
isolates had the same resistant phenotype of this strain. 
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Moreover, an important increase in the resistance rates 
occurred from 2008 to 2014, increasing from 35% to 
82.8% for imipenem and from 0% to 19.1% for colistin 
[3,4]. This increasing trend has also been observed in 
previous Pan American Health Organization (PAHO) 
and nationwide reports [5,6]. The results obtained in 
this hospital are comparable to those found in other 
countries of Central and South America, such as 
Mexico (76%), Argentina (78%), Panama (77%), 
Guatemala (64%), Colombia (> 60%), and Brazil 
(56%), and higher that the values described in 
Honduras, El Salvador, Nicaragua, and Chile (20%) 
[5,6]. 
As the detection of carbapenem-resistant A. 
baumannii isolates is a worrying event that requires 
rapid control measures, we decided to thoroughly 
investigate the presence of carbapenem-hydrolyzing 
enzymes, focusing on OXA-type carbapenemases, 
which are the most prevalent in this species [2]. 
Multiplex polymerase chain reaction (PCR) to search 
for OXA-type families (-23 like, -40 like, -51 like, -58 
like, and -143 like) was performed, showing the 
presence of the blaOXA-51-like and blaOXA-23-like 
carbapenemase genes. Further sequencing experiments 
showed 100% homology with the blaOXA-23 gene as 
previously described [2]. This isolate represented the 
first description of the OXA-23 carbapenemase in 
isolates of A. baumannii from Cochabamba, Bolivia [7]. 
In addition, we found that both blaOXA-23 and blaOXA-51 
genes were related to ISAba1 insertion sequences 
upstream that leads to the overexpression of the 
enzymes [1,2]. PCR experiments for detecting other 
metallo-β-lactamases (VIM, IMP, GIM, SIM, and 
NDM) were negative. 
In our group’s previous study, carried out in the 
same hospital in 2008, an outbreak of 15 multidrug-
resistant Acinetobacter baumannii isolates belonging to 
a unique clone and producing the OXA-51 and OXA-
58 carbapenemases was reported, and represented the 
first description of OXA-type enzymes in Bolivia [4]. 
At present, strain Bo995 represents the first isolate 
harboring the blaOXA-23 carbapenemase gene in 
Cochabamba, Bolivia [7]. Detection of new 
carbapenemase families in this hospital is of great 
concern, as it confirms the spread of carbapenem-
resistant isolates in the same hospital environment, in 
the country (where an OXA-23 carbapenemase-
producing isolate was recently reported [8]), and along 
the continent [6]. The blaOXA-23 carbapenemase gene 
was first detected in Edinburgh [9] and has been 
identified worldwide. In Latin America, Brazil was, in 
2003, the first country to report OXA-23-producing 
isolates, followed some years later by Colombia, 
Argentina, and México [10-15]. 
The blaOXA-51 gene is usually located on the 
chromosome, but the blaOXA-23 gene has been reported 
to be encoded also by plasmids of different sizes (from 
25 to 200 kb) or on the chromosome. To analyze the 
presence of these mobile structures and locate the 
genes, plasmid DNA was extracted with a commercial 
midi plasmid extraction kit (Qiagen, Hilden, Germany) 
and by pulsed-field gel electrophoresis (PFGE) with S1 
enzyme (Takara, Otsu, Japan). Plasmid size was 
determined by comparison with those from the standard 
strains Escherichia coli NCTC 50193 and NCTC 59192 
(National Collection of Type Cultures, Salisbury, UK), 
containing plasmids ranging in size from 2 to 163.3 kb. 
Plasmids of 2.7, 5.7, 6.8, and 34 kb were detected by 
the commercial kit, and a plasmid of 180 kb was 
detected by PFGE. (Figure 1). 
To locate the blaOXA-51-like and the blaOXA-23 genes, 
gels were transferred to a nylon membrane and 
Southern blot was performed with specific PCR-
generated probes labeled with dUTP-digoxigenin 
(Roche, Mannheim, Germany). Detection of hybrids 
Figure 1. Plasmid profile of isolate Bo995. 
A. Plasmid extraction with a commercial kit. Lane 1: control strain E. 
coli NCTC  50193 containing plasmids ranging in size from 2 to 53.3 kb; 
lane 2: control strain E. coli NCTC 59192 containing plasmids ranging 
in size from 7.6 to 163.3 kb; lane 3: plasmid profile of isolate Bo995 with 
structures of 2.7, 5.7, 6.8, and 34 kb; chr: chromosome; M: molecular 
weight marker dig-labelled. B. Plasmid detection by PFGE with S1. Lane 
1: low range PFG marker (Biolabs); lane 2: isolate Bo995. 
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was done using an anti-digoxigenin antibody coupled 
with alkaline phosphatase, following the 
manufacturer’s instructions (Roche, Mannheim, 
Germany). Hybridization experiments located both the 
blaOXA-51 and the blaOXA-23 gene on the chromosome. 
Typing experiments to determine clonal 
relationship with other worldwide genotypes revealed 
that Bo995 did not belong to international clones I, II, 
or III. Moreover, no homology was found with isolates 
that had been previously identified in the same hospital 
[3,4]. The dissemination of the blaOXA-23 gene through 
South America has been related to both monoclonal and 
polyclonal spread [6,14], so further genotypic analysis 
is needed to demonstrate the epidemiological origin of 
Bo995, and in-depth surveillance studies must be 
carried out in order to prevent the spread of this strain. 
 
Conclusions 
This is the first description of an OXA-23 
carbapenemase-producing A. baumannii isolate in 
Cochabamba, Bolivia. It is the second acquired OXA-
type enzyme described in the country, as a multidrug-
resistant Acinetobacter baumannii clone producing 
OXA-58 were previously identified in the same hospital 
during 2008. 
Both blaOXA-51 and blaOXA-23 genes were located on 
the chromosome and related to an ISAba1 upstream, 
which contributes to the overexpression of the enzymes. 
The detection of new carbapenemase-producing 
strains in this hospital of Cochabamba, Bolivia, 
highlights the need to implement control measures to 
stop the spread of this isolate among the nosocomial 
environment. 
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